MyMD Pharmaceuticals, Inc.

Equities

MYMD

US62856X2018

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 01:49:48 2024-04-19 pm EDT			5-day change	1st Jan Change
2.55 ^USD	+1.19%		+5.00%	-67.53%

Apr. 09	Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data	MT
Apr. 09	Investors Eye Wednesday Inflation Data as US Futures Tread Water Tuesday Pre-Bell	MT

AKERS BIOSCIENCES, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

November 18, 2020 at 04:54 pm EST

Item 8.01 Other Events.

On November 18, 2020, Akers Biosciences, Inc. (the "Company") issued a press release announcing that MyMD Pharmaceuticals, Inc. and the Company plan to hold a video conference for investors on Wednesday, November 18, 2020 at 4:15 p.m. ET to provide additional context on the integrated company, the clinical pipeline and drug development plan, and the commercial potential of the targeted indications. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits



Exhibit
Number                    Description
99.1        Press release, dated November 18, 2020.

Latest news about MyMD Pharmaceuticals, Inc.

Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data	Apr. 09	MT
Investors Eye Wednesday Inflation Data as US Futures Tread Water Tuesday Pre-Bell	Apr. 09	MT
Top Premarket Gainers	Apr. 09	MT
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
MyMD Pharmaceuticals Regains Compliance With Nasdaq's Minimum Bid Listing Requirement	Mar. 05	MT
MyMD Pharmaceuticals to Implement 1-for-30 Reverse Stock Split	Feb. 13	MT
MyMD Pharmaceuticals, Inc. Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis	Dec. 06	CI
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Mymd Pharmaceuticals, Inc. Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD, Reduced Acute Inflammatory Pain	23-10-19	CI
MyMD Pharmaceuticals, Inc. to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-a Market Disrupter, at BioFuture 2023	23-10-04	CI
MyMD Pharmaceuticals, Inc.(NasdaqCM:MYMD) dropped from S&P Global BMI Index	23-09-18	CI
Insider Buy: Mymd Pharmaceuticals	23-08-24	MT
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
MyMD Pharmaceuticals Says Its Investigational New Drug Application for Rheumatoid Arthritis Treatment Gets FDA Acceptance	23-08-14	MT
FDA Accepts MyMD Pharmaceuticals, Inc. Investigational New Drug Application for Phase 2 Study of Oral Tnf-A Inhibitor Mymd-1®? in Rheumatoid Arthritis	23-08-14	CI
MyMD Pharmaceuticals' MYMD-1 Study Shows Positive Results for Age-Related inflammation Drug; Shares Rise	23-07-31	MT
Mymd Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral Tnf-A Inhibitor Mymd-1® in Sarcopenia/Age-Related Frailty	23-07-31	CI
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
MyMD Pharmaceuticals Says Phase 2 Trial of Treatment for Sarcopenia, Frailty Shows No Safety Issues	23-04-12	MT
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
MyMD Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	23-03-30	CI
Mymd Pharmaceuticals, Inc. to Present Data from Preclinical Study of its MYMD-1 Product Candidate in A Rheumatoid Arthritis (Ra) Model at the 2023 Society of Toxicology Annual Meeting	23-03-20	CI
MyMD Pharmaceuticals' Supera-CBD Determined by US Drug Enforcement Administration as Not Controlled Substance	23-03-02	MT
MyMD Pharmaceuticals, Inc. Announces U.S. Drug Enforcement Administration Determines Supera-CBD Is Not A Controlled Substance or Listed Chemical	23-03-02	CI
MyMD Pharmaceuticals, Inc. Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data for Oral TNF-Inhibitor MYMD-1 at the Society of Toxicology 2023 Annual Meeting	23-02-28	CI

Chart MyMD Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. The Companyâs MYMD-1 is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. It also shows potential as an anti-fibrotic and anti-prolific therapeutic. The Companyâs second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. Supera-CBD is a synthetic, preclinical cannabidiol derivative that has been demonstrated to effectively target cannabinoid type 2 (CB2) receptors. Supera-CBD binds to and inhibits opioid receptors, comparing it side by side with plant-based cannabidiol (CBD).

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MYMD PHARMACEUTICALS, INC.	-67.53%	5.44M
VERTEX PHARMACEUTICALS INCORPORATED	-2.92%	102B
REGENERON PHARMACEUTICALS, INC.	+1.81%	96.07B
ARGENX SE	-1.80%	21.66B
BIONTECH SE	-17.89%	20.77B
GENMAB A/S	-6.91%	18.53B
WUXI APPTEC CO., LTD.	-42.00%	16.91B
BEIGENE, LTD.	-27.92%	13.79B
NEUROCRINE BIOSCIENCES, INC.	-0.01%	13.33B
SAREPTA THERAPEUTICS, INC.	+19.06%	10.94B

Bio Therapeutic Drugs